Announcement of webinar 【MASH-Liver cancer model mouse_Pharmacology study for MASH/fibrosis targeting GLP-1】
- NEWS RELEASE
Today, we are excited to invite you to join our Webinar that will be taking place on January 25th from 9:30 AM (JST).
In this webinar, we will introduce the drug evaluation study with GLP-1. That is why we highly recommend that you join our free webinar!
Webinar Link ►►► Click here
【 Webinar Outline 】
Title: MASH-Liver cancer model mouse_Pharmacology study for MASH/fibrosis targeting GLP-1
SMC Laboratories is a non-clinical, consulting-type CRO that provides contract services for pharmacology studies that utilize technology and know-how related to MASH, inflammation, fibrosis, metabolism, and cancer immunity. In non-clinical studies using STAM™ model, a MASH-liver cancer model that we independently developed, we have so far evaluated the efficacy of more than 800 compounds against steatosis, MASH, fibrosis, and liver cancer. We have evaluated over 15 MOA categories and over 270 target molecules. In this webinar, we will introduce an example of a pharmacology studies using STAM™ model. This time, we will introduce examples of drug efficacy evaluations targeting GLP-1.
Date and time: January 25 (Thu), 9:30 - 10:00 (JST)
Attend this webinar to:
● Introduce about SMC Laboratories
● Introduce about our MASH-HCC model
● Example of drug efficacy evaluation targeting GLP-1
- GLP-1 analog
- DDP-4 inhibitor
- GPR119 receptor agonist
If you have any interest or questions, please feel free to contact us.